138 related articles for article (PubMed ID: 32754733)
1. Tofacitinib in antisynthetase syndrome-related rapidly progressive interstitial lung disease.
Pineton de Chambrun M; Hervier B; Chauveau S; Tandjaoui-Lambiotte Y; Combes A; Uzunhan Y
Rheumatology (Oxford); 2020 Dec; 59(12):e142-e143. PubMed ID: 32754733
[No Abstract] [Full Text] [Related]
2. Tofacitinib in Amyopathic Dermatomyositis-Associated Interstitial Lung Disease.
Chen Z; Wang X; Ye S
N Engl J Med; 2019 Jul; 381(3):291-293. PubMed ID: 31314977
[No Abstract] [Full Text] [Related]
3. Efficacy of tofacitinib for slowly progressive interstitial lung disease in a patient with anti-MDA5 antibody-positive dermatomyositis.
Takatani A; Koga T; Fujita Y; Fukui S; Endo Y; Shimizu T; Kawakami A
Clin Immunol; 2020 Jun; 215():108451. PubMed ID: 32360518
[No Abstract] [Full Text] [Related]
4. Janus kinase inhibition in induction treatment of anti-MDA5 juvenile dermatomyositis-associated rapidly progressive interstitial lung disease.
Chan Ng PLP; Mopur A; Goh DYT; Ramamurthy MB; Lim MTC; Lim LK; Ooi PL; Ang EY
Int J Rheum Dis; 2022 Feb; 25(2):228-231. PubMed ID: 34882988
[TBL] [Abstract][Full Text] [Related]
5. Interstitial lung disease associated with the idiopathic inflammatory myopathies and the antisynthetase syndrome: recent advances.
Hallowell RW; Danoff SK
Curr Opin Rheumatol; 2014 Nov; 26(6):684-9. PubMed ID: 25203119
[TBL] [Abstract][Full Text] [Related]
6. STING-Associated Vasculopathy with Onset in Infancy in Three Children with New Clinical Aspect and Unsatisfactory Therapeutic Responses to Tofacitinib.
Tang X; Xu H; Zhou C; Peng Y; Liu H; Liu J; Li H; Yang H; Zhao S
J Clin Immunol; 2020 Jan; 40(1):114-122. PubMed ID: 31705453
[TBL] [Abstract][Full Text] [Related]
7. [Acute interstitial lung disease revealing antisynthetase syndrome].
Bizien N; Renault A; Boles JM; Delluc A
Rev Pneumol Clin; 2011 Dec; 67(6):367-70. PubMed ID: 22137282
[TBL] [Abstract][Full Text] [Related]
8. Rituximab in the Treatment of Interstitial Lung Disease Associated with Antisynthetase Syndrome: A Multicenter Retrospective Case Review.
Doyle TJ; Dhillon N; Madan R; Cabral F; Fletcher EA; Koontz DC; Aggarwal R; Osorio JC; Rosas IO; Oddis CV; Dellaripa PF
J Rheumatol; 2018 Jun; 45(6):841-850. PubMed ID: 29606668
[TBL] [Abstract][Full Text] [Related]
9. Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis.
Kurasawa K; Arai S; Namiki Y; Tanaka A; Takamura Y; Owada T; Arima M; Maezawa R
Rheumatology (Oxford); 2018 Dec; 57(12):2114-2119. PubMed ID: 30060040
[TBL] [Abstract][Full Text] [Related]
10. Interstitial lung disease in a child with antisynthetase syndrome.
Hayes D; Baker PB; Mansour HM; Peeples ME; Nicol KK
Lung; 2013 Aug; 191(4):441-3. PubMed ID: 23652349
[TBL] [Abstract][Full Text] [Related]
11. Antisynthetase syndrome: not just an inflammatory myopathy.
Chatterjee S; Prayson R; Farver C
Cleve Clin J Med; 2013 Oct; 80(10):655-66. PubMed ID: 24085811
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Treatment With Azathioprine and Mycophenolate Mofetil for Myositis-Related Interstitial Lung Disease.
Huapaya JA; Silhan L; Pinal-Fernandez I; Casal-Dominguez M; Johnson C; Albayda J; Paik JJ; Sanyal A; Mammen AL; Christopher-Stine L; Danoff SK
Chest; 2019 Nov; 156(5):896-906. PubMed ID: 31238042
[TBL] [Abstract][Full Text] [Related]
13. Veno-Venous Extracorporeal Membrane Oxygenation for Myositis-Associated Rapidly Progressive Interstitial Lung Disease.
Rubin J; Black KE; Hallowell RW; Witkin AS; Lydston M; Shelton K; Crowley J; Vogel Y; Raz Y
Chest; 2021 Dec; 160(6):2163-2167. PubMed ID: 34284003
[No Abstract] [Full Text] [Related]
14. Interstitial lung disease as first clinical manifestation within the antisynthetase syndrome--dermatomyositis.
Trăilă D; Mlădinescu OF; Oancea C; Tudorache V
Pneumologia; 2015; 64(2):37-40. PubMed ID: 26506673
[TBL] [Abstract][Full Text] [Related]
15. [The efficacy and safety of the rituximab in anti-synthetase syndrome associated interstitial lung disease: a literature review].
Mao MM; Guo BP; Han Q
Zhonghua Jie He He Hu Xi Za Zhi; 2019 Oct; 42(10):776-779. PubMed ID: 31594113
[TBL] [Abstract][Full Text] [Related]
16. Pulmonary manifestations in antisynthetase syndrome.
Ben Salem T; Abdelkafi C; Lamloum M; Ben Ghorbel I; Houman MH
Tunis Med; 2018 Feb; 96(2):101-106. PubMed ID: 30324974
[TBL] [Abstract][Full Text] [Related]
17. Antisynthetase syndrome with refractory lung involvement and myositis successfully treated with double filtration plasmapheresis.
Bozkirli DE; Kozanoglu I; Bozkirli E; Yucel E
J Clin Apher; 2013 Dec; 28(6):422-5. PubMed ID: 23908096
[TBL] [Abstract][Full Text] [Related]
18. Presymptomatic myositis in patients with antisynthetase syndrome associated with interstitial lung disease: A prospective small case series clinical study.
Ozaki M; Mano T; Iwasa N; Yamamoto Y; Takatani T; Kido A; Sugie K
Int J Rheum Dis; 2023 Oct; 26(10):2100-2103. PubMed ID: 37218544
[No Abstract] [Full Text] [Related]
19. Successful Treatment of Life-Threatening Interstitial Lung Disease Secondary to Antisynthetase Syndrome Using Rituximab: A Case Report and Review of the Literature.
Dasa O; Ruzieh M; Oraibi O
Am J Ther; 2016; 23(2):e639-45. PubMed ID: 25830868
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment of extensive calcifications and acute pulmonary involvement in dermatomyositis with the Janus-Kinase inhibitor tofacitinib - A report of two cases.
Wendel S; Venhoff N; Frye BC; May AM; Agarwal P; Rizzi M; Voll RE; Thiel J
J Autoimmun; 2019 Jun; 100():131-136. PubMed ID: 30862449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
